Zealand Pharma A/s(OTC) ZLDPF

Zealand Pharma A/S is a biotechnology company based in Copenhagen, Denmark, focused on the entire lifecycle of peptide-based medicines. The company specializes in developing treatments for gastrointestinal and metabolic disorders, with a strong emphasis on addressing unmet medical needs.

Products and Services

• Adlyxin and Lyxumia, marketed forms of lixisenatide
• Dasiglucagon, a treatment for severe hypoglycemia and congenital hyperinsulinism
• Robust pipeline including glepaglutide for short bowel syndrome

Growth Outlook

• Dasiglucagon is advancing through Phase III trials for congenital hyperinsulinism
• Glepaglutide is also in Phase III trials, targeting short bowel syndrome
• Strategic collaborations with major pharmaceutical companies enhance growth potential

Financial Highlights

• Recent quarterly revenue of 34.04 million DKK, showing a strong market presence
• TTM net profit margin stands at 69.2%, indicating operational efficiency
• Current ratio of 37.17 suggests strong liquidity and financial health

Zealand Pharma A/S operates in a dynamic sector with a focus on innovative peptide-based therapies. The company's current products, such as Adlyxin and Dasiglucagon, are already addressing critical health issues, while its development pipeline promises further advancements in treatment options. The ongoing clinical trials for Dasiglucagon and glepaglutide highlight the company's commitment to expanding its therapeutic offerings. Financially, the company demonstrates a solid revenue stream and impressive profit margins, reflecting its operational effectiveness. With strategic partnerships in place, Zealand Pharma A/S is well-positioned for future growth in the biotechnology landscape.